HLP
Hongli Group Inc.·Basic Materials
0.89
0.452%(+0.00)
Market ClosedLast Updated: — ET
52W L: $0.6152W H: $1.82
HLP NEWS
defenseworld.net
Mar 26
Hongli Group Inc. (NASDAQ:HLP) Short Interest Down 59.1% in March
Hongli Group Inc. (NASDAQ: HLP - Get Free Report) was the recipient of a significant decline in short interest during the month of March. As of March 13th, there was short interest totaling 7,543 shares, a decline of 59.1% from the February 26th total of 18,436 shares. Based on an average trading volume of 66,320 shares,
globenewswire.com
Mar 5
Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder
Statistically significant (p
seekingalpha.com
Feb 24
HELUS Pharma: Transitioning From Psychedelic Research To Late-Stage Clinical Neuroscience
HELUS Pharma has rebranded and moved to Nasdaq, signaling a shift toward late-stage clinical development and commercial focus. Key 2026 catalysts include Phase 3 data for HLP003 in major depressive disorder and Phase 2 data for HLP004 in generalized anxiety disorder. HELP's cash burn accelerated to $36.7M in 3Q26, with $195M cash on hand and a $100M ATM facility providing runway through pivotal trial milestones.
